All Stories

  1. Chemoembolization using streptozotocin versus embolization in metastatic NETs

    Article • Endocrine Related Cancer, December 2025, Bioscientifica

    Dr Jerome Cros

  2. DNA methylation patterns facilitate tracing the origin of neuroendocrine neoplasms

    Article • Nature Communications, October 2025, Springer Science + Business Media

    Dr Jerome Cros

  3. Predictive value of metabolic state on PanNET response to mTOR inhibitors

    Article • Endocrine Related Cancer, September 2025, Bioscientifica

    Dr Jerome Cros

  4. Temporal increase in Ki-67 index in patients with pancreatic neuroendocrine tumours

    Article • Endocrine Related Cancer, January 2025, Bioscientifica

    Dr Jerome Cros

  5. Une tumeur neuroendocrine pancréatique kystique bien spéciale

    Article • Annales de Pathologie, November 2023, Elsevier

    Dr Jerome Cros

  6. AGAP3: A novel BRAF fusion partner in pediatric pancreatic‐type acinar cell carcinoma

    Article • Genes Chromosomes and Cancer, August 2022, Wiley

    Dr Jerome Cros

  7. Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review of Clinical-Pathological Features, Outcomes, and Molecular Insights

    Article • International Journal of Molecular Sciences, June 2021, MDPI AG

    Dr Jerome Cros

  8. Nucleolin Targeting by N6L Inhibits Wnt/β-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma

    Article • Cancers, June 2021, MDPI AG

    Dr Jerome Cros

  9. Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features

    Article • Cancers, March 2021, MDPI AG

    Dr Jerome Cros

  10. Biomarkers of Response to Etoposide-Platinum Chemotherapy in Patients with Grade 3 Neuroendocrine Neoplasms

    Article • Cancers, February 2021, MDPI AG

    Dr Jerome Cros

  11. Familial Pancreatic Intraductal Papillary and Mucinous Neoplasms Do Not Carry Constitutional or Postzygotic GNAS Activating Mutations

    Article • Pancreas, February 2021, Wolters Kluwer Health

    Dr Jerome Cros

  12. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma

    Article • Annals of Oncology, February 2021, Elsevier

    Dr Jerome Cros

  13. Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages

    Article • Cellular and Molecular Gastroenterology and Hepatology, January 2021, Elsevier

    Dr Jerome Cros

  14. O-positive blood type is associated with prolonged recurrence-free survival following curative resection of pancreatic neuroendocrine tumors

    Article • Pancreatology, December 2020, Elsevier

    Dr Jerome Cros

  15. Morphological imaging and CT histogram analysis to differentiate pancreatic neuroendocrine tumor grade 3 from neuroendocrine carcinoma

    Article • Diagnostic and Interventional Imaging, December 2020, Elsevier

    Dr Jerome Cros

  16. Caractéristiques clinicopathologiques et résultats postopératoires de l’entérite radio-induite : une étude rétrospective de 41 patients

    Article • Annales de Pathologie, November 2020, Elsevier

    Dr Jerome Cros

  17. Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer

    Article • Cancers, October 2020, MDPI AG

    Dr Jerome Cros

  18. CT-Based Radiomics Analysis to Predict Malignancy in Patients with Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas

    Article • Cancers, October 2020, MDPI AG

    Dr Jerome Cros

  19. FAK activity in cancer‐associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer

    Article • EMBO Molecular Medicine, October 2020, Springer Science + Business Media

    Dr Jerome Cros

  20. Critical appraisal of MGMT in digestive NET treated with alkylating agents

    Article • Endocrine Related Cancer, October 2020, Bioscientifica

    Dr Jerome Cros

  21. Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma

    Article • Clinical Cancer Research, October 2020, American Association for Cancer Research (AACR)

    Dr Jerome Cros

  22. PARP inhibition in treatment of pancreatic cancer

    Article • Expert Review of Anticancer Therapy, September 2020, Taylor & Francis

    Dr Jerome Cros

  23. Recurrent acute pancreatitis caused by combined gastric and pancreatic duplications: value of preoperative CT and MRCP and conservative surgery

    Article • Journal of Surgical Case Reports, August 2020, Oxford University Press (OUP)

    Dr Jerome Cros

  24. Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer

    Article • EBioMedicine, July 2020, Elsevier

    Dr Jerome Cros

  25. DECONbench: a benchmarking platform dedicated to deconvolution methods for tumor heterogeneity quantification

    Article • June 2020, Cold Spring Harbor Laboratory Press

    Dr Jerome Cros

  26. Correction to: Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging

    Article • European Radiology, June 2020, Springer Science + Business Media

    Dr Jerome Cros

  27. 22G Acquire vs. 20G Procore needle for endoscopic ultrasound-guided biopsy of pancreatic masses: a randomized study comparing histologic sample quantity and diagnostic accuracy

    Article • Endoscopy, May 2020, Thieme Publishing Group

    Dr Jerome Cros

  28. Could pancreatic grade 3 neuroendocrine tumors really behave similarly to neuroendocrine carcinomas following resection?

    Article • HPB, May 2020, Elsevier

    Dr Jerome Cros

  29. Erratum to ‘Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial’ [European Journal of Cancer, Volume 124 (January 2020) Pages 91-...

    Article • European Journal of Cancer, May 2020, Elsevier

    Dr Jerome Cros

  30. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes

    Article • Gastroenterology, April 2020, Elsevier

    Dr Jerome Cros

  31. Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer

    Article • March 2020, Cold Spring Harbor Laboratory Press

    Dr Jerome Cros

  32. Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference?

    Article • Neuroendocrinology, March 2020, Karger Publishers

    Dr Jerome Cros

  33. Specific Genomic Alterations in High-Grade Pulmonary Neuroendocrine Tumours with Carcinoid Morphology

    Article • Neuroendocrinology, February 2020, Karger Publishers

    Dr Jerome Cros

  34. The histone acetyltransferase hMOF promotes vascular invasion in hepatocellular carcinoma

    Article • Liver International, January 2020, Wiley

    Dr Jerome Cros

  35. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial

    Article • European Journal of Cancer, January 2020, Elsevier

    Dr Jerome Cros

  36. The postoperative occurrence or worsening of diabetes mellitus may increase the risk of recurrence in resected pancreatic neuroendocrine tumors

    Article • Neuroendocrinology, December 2019, Karger Publishers

    Dr Jerome Cros

  37. Lesion-by-lesion correlation between uptake at FDG PET and the Ki67 proliferation index in resected pancreatic neuroendocrine tumors

    Article • Digestive and Liver Disease, December 2019, Elsevier

    Dr Jerome Cros

  38. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status

    Article • Cancers, November 2019, MDPI AG

    Dr Jerome Cros

  39. Prognostic Factors of Acinar Cell Carcinomas

    Article • Pancreas, November 2019, Wolters Kluwer Health

    Dr Jerome Cros

  40. Endoscopic, transanal, laparoscopic, and transabdominal management of rectal neuroendocrine tumors

    Article • Best Practice & Research Clinical Endocrinology & Metabolism, October 2019, Elsevier

    Dr Jerome Cros

  41. ASO Author Reflections: What Will Be the Future of IPMN Management?

    Article • Annals of Surgical Oncology, September 2019, Springer Science + Business Media

    Dr Jerome Cros

  42. Familial pancreatic adenocarcinoma: A retrospective analysis of germline genetic testing in a French multicentre cohort

    Article • Clinical Genetics, September 2019, Wiley

    Dr Jerome Cros

  43. High Positive Correlations between ANRIL and p16-CDKN2A/p15-CDKN2B/p14-ARF Gene Cluster Overexpression in Multi-Tumor Types Suggest Deregulated Activation of an ANRIL–ARF Bidirectional Promoter

    Article • Non-Coding RNA, August 2019, MDPI AG

    Dr Jerome Cros

  44. Extended Laparoscopic Central Pancreatectomy with Clamping of the Mesentericoportal Vein and Resection of the Splenic Vessels for a Large Solid Pseudopapillary Tumor

    Article • Annals of Surgical Oncology, August 2019, Springer Science + Business Media

    Dr Jerome Cros

  45. Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi)

    Article • Frontiers in Oncology, June 2019, Frontiers

    Dr Jerome Cros

  46. KrasandLkb1mutations synergistically induce intraductal papillary mucinous neoplasm derived from pancreatic duct cells

    Article • Gut, June 2019, BMJ

    Dr Jerome Cros

  47. Digestive system mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN)

    Article • Annales d Endocrinologie, June 2019, Elsevier

    Dr Jerome Cros

  48. Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor

    Article • Neuroendocrinology, May 2019, Karger Publishers

    Dr Jerome Cros

  49. GNAS but Not Extended RAS Mutations Spectrum are Associated with a Better Prognosis in Intraductal Pancreatic Mucinous Neoplasms

    Article • Annals of Surgical Oncology, April 2019, Springer Science + Business Media

    Dr Jerome Cros

  50. Non-branched microcysts of the pancreas on MR imaging of patients with pancreatic tumors who had pancreatectomy may predict the presence of pancreatic intraepithelial neoplasia (PanIN): a preliminary study

    Article • European Radiology, April 2019, Springer Science + Business Media

    Dr Jerome Cros

  51. O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET)

    Article • Digestive and Liver Disease, April 2019, Elsevier

    Dr Jerome Cros

  52. Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study

    Article • British Journal of Cancer, March 2019, Springer Science + Business Media

    Dr Jerome Cros

  53. Comparison of temozolomide-capecitabine to 5-fluorouracile-dacarbazine in 247 patients with advanced digestive neuroendocrine tumors using propensity score analyses

    Article • Neuroendocrinology, February 2019, Karger Publishers

    Dr Jerome Cros

  54. Prognostic Biomarkers in Pancreatic Cancer: Avoiding Errata When Using the TCGA Dataset

    Article • Cancers, January 2019, MDPI AG

    Dr Jerome Cros

  55. Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma

    Article • Clinical Cancer Research, January 2019, American Association for Cancer Research (AACR)

    Dr Jerome Cros

  56. Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level meta-analysis and proposition of the Beaujon score

    Article • United European Gastroenterology Journal, January 2019, SAGE Publications

    Dr Jerome Cros

  57. Inter- and intra-tumoral heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma

    Article • The Journal of Pathology, December 2018, Wiley

    Dr Marie Tosolini, Dr Jerome Cros

  58. Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome

    Article • Oncogene, December 2018, Springer Science + Business Media

    Dr Jerome Cros

  59. Proteomic Landscape of Cholangiocarcinomas Reveals Three Different Subgroups According to Their Localization and the Aspect of Non‐Tumor Liver

    Article • PROTEOMICS - CLINICAL APPLICATIONS, December 2018, Wiley

    Dr Jerome Cros

  60. Sporadic pancreatic neuroendocrine tumor: Surgery of the primary tumor

    Article • Journal of Visceral Surgery, December 2018, Elsevier

    Dr Jerome Cros

  61. Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features

    Article • Gastroenterology, December 2018, Elsevier

    Dr Jerome Cros

  62. PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications

    Article • Human Pathology, November 2018, Elsevier

    Dr Jerome Cros

  63. A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort

    Article • BMC Cancer, October 2018, Springer Science + Business Media

    Dr Jerome Cros

  64. COMPETITIVE TESTING THE WHO 2010 VS THE WHO 2017 GRADING OF PANCREAS NEUROENDOCRINE NEOPLASIA: DATA FROM A LARGE INTERNATIONAL COHORT STUDY

    Article • Neuroendocrinology, October 2018, Karger Publishers

    Dr Jerome Cros, Prof Wouter WW de Herder

  65. Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future

    Article • Digestive and Liver Disease, October 2018, Elsevier

    Dr Jerome Cros

  66. Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos)

    Article • Gastrointestinal Endoscopy, June 2018, Elsevier

    Dr Jerome Cros

  67. Array comparative genomic hybridization identifies high level of PI3K/Akt/mTOR pathway alterations in anal cancer recurrences

    Article • Cancer Medicine, May 2018, Wiley

    Dr Jerome Cros

  68. Preoperative imaging and pathologic classification for pancreatic neuroendocrine tumors

    Article • Journal of Visceral Surgery, April 2018, Elsevier

    Dr Jerome Cros

  69. A false postoperative recurrence of intraductal and papillary mucinous neoplasm of the pancreas

    Article • Journal of Visceral Surgery, April 2018, Elsevier

    Dr Jerome Cros

  70. Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas

    Article • Gastroenterology, March 2018, Elsevier

    Dr Jerome Cros

  71. In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma

    Article • Oncotarget, January 2018, Impact Journals, LLC

    Dr Jerome Cros

  72. La caractérisation moléculaire définit plusieurs sous-types d’adénocarcinome canalaire du pancréas

    Article • Bulletin du Cancer, January 2018, Elsevier

    Dr Jerome Cros

  73. Gastric stump carcinoma as a long-term complication of pancreaticoduodenectomy: report of two cases and review of the English literature

    Article • BMC Gastroenterology, November 2017, Springer Science + Business Media

    Dr Jerome Cros

  74. Contribution of virtual biopsy to the screening of microvascular invasion in hepatocellular carcinoma: A pilot study

    Article • Liver International, September 2017, Wiley

    Dr Jerome Cros

  75. 18F-FDG uptake in well-differentiated neuroendocrine tumors correlates with both Ki-67 and VHL pathway inactivation

    Article • Neuroendocrinology, August 2017, Karger Publishers

    Dr Jerome Cros

  76. Tumor Heterogeneity in Pancreatic Adenocarcinoma

    Article • Pathobiology, August 2017, Karger Publishers

    Dr Jerome Cros

  77. The Largest European Single-Center Experience: 300 Laparoscopic Pancreatic Resections

    Article • Journal of the American College of Surgeons, August 2017, Elsevier

    Dr Jerome Cros

  78. 5-Fluorouracil biomarkers in pancreatic neuroendocrine tumours

    Article • Pancreatology, July 2017, Elsevier

    Dr Jerome Cros

  79. PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker

    Article • Cellular and Molecular Life Sciences, June 2017, Springer Science + Business Media

    Dr Jerome Cros

  80. Surgical Ampullectomy with Complete Resection of the Common Bile Duct: a New Procedure for Radical Resection of Non-invasive Ampulloma with Biliary Extension

    Article • Journal of Gastrointestinal Surgery, May 2017, Springer Science + Business Media

    Dr Jerome Cros

  81. Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms

    Article • Neuroendocrinology, January 2017, Karger Publishers

    Dr Jerome Cros

  82. Investigation at the micrometer scale of pancreatic calcifications in chronic pancreatitis by μFTIR spectroscopy and field emission scanning electron microscopy

    Article • Comptes Rendus Chimie, November 2016, Elsevier

    Dr Jerome Cros

  83. Stage-dependent fate of Plasmodium falciparum-infected red blood cells in the spleen and sickle-cell trait-related protection against malaria

    Article • Malaria Journal, September 2016, Springer Science + Business Media

    Dr Jerome Cros

  84. Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging

    Article • European Radiology, August 2016, Springer Science + Business Media

    Dr Hossein Lotfalizadeh, Dr Jerome Cros

  85. Pancreatic ductal adenocarcinoma inBRCA2mutation carriers: Table 1

    Article • Endocrine Related Cancer, August 2016, Bioscientifica

    Dr Jerome Cros

  86. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors

    Article • Endocrine Related Cancer, June 2016, Bioscientifica

    Dr Jerome Cros

  87. Accuracy of 2012 International Consensus Guidelines for the prediction of malignancy of branch-duct intraductal papillary mucinous neoplasms of the pancreas

    Article • United European Gastroenterology Journal, June 2016, SAGE Publications

    Dr Enrique Perez-Cuadrado Robles, Dr Jerome Cros

  88. Nestin expression on tumour vessels and tumour-infiltrating macrophages define a poor prognosis subgroup of pt1 clear cell renal cell carcinoma

    Article • Virchows Archiv, June 2016, Springer Science + Business Media

    Dr Jerome Cros

  89. Well differentiated pancreatic neuroendocrine tumors (WDPNET) G3: Does the Ki67 really do it all?

    Article • Pancreatology, June 2016, Elsevier

    Dr Jerome Cros

  90. Metabolic state may define and predict resistance to mTOR-targeting therapies in pancreatic neuroendocrine tumors

    Article • Pancreatology, June 2016, Elsevier

    Dr Jerome Cros

  91. Distal intramural and tumor spread in the mesorectum after neoadjuvant radiochemotherapy in rectal cancer: about 124 consecutive patients

    Article • Human Pathology, June 2016, Elsevier

    Dr Jerome Cros

  92. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution

    Article • Oncotarget, May 2016, Impact Journals, LLC

    Dr Jerome Cros

  93. State of the art and future directions of pancreatic ductal adenocarcinoma therapy

    Article • Pharmacology & Therapeutics, November 2015, Elsevier

    Dr Jerome Cros

  94. Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma

    Article • Pancreas, October 2015, Wolters Kluwer Health

    Dr Jerome Cros

  95. Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors

    Article • Neuroendocrinology, September 2015, Karger Publishers

    Dr Jerome Cros

  96. Parenchyma-sparing pancreatectomies for pancreatic neuroendocrine tumors

    Article • International Journal of Endocrine Oncology, August 2015, Future Medicine

    Dr Jerome Cros

  97. Abstract 580: hENT1 testing in pancreatic ductal adenocarcinoma: Are we ready yet? A comparative analysis of the murine and the rabbit antibodies

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Dr Jerome Cros

  98. Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place

    Article • Annals of Surgery, August 2015, Wolters Kluwer Health

    Dr Jerome Cros

  99. Gly388Arg FGFR4 polymorphism is not predictive of everolimus efficacy in well-differentiated digestive neuroendocrine tumors

    Article • Pancreatology, June 2015, Elsevier

    Dr Jerome Cros

  100. Comparative analysis between Sendai guidelines and the European experts consensus statement on BD-IPMN of the pancreas

    Article • Pancreatology, June 2015, Elsevier

    Dr Jerome Cros

  101. Decreased pS6 expression under MEK inhibitor (MEKi) correlates with response to MEKi alone or combined with PI3Ki-mTOR inhibitor (PI3Ki-mTORi) in pancreatic adenocarcinoma (PAC) in vitro and ex vivo models

    Article • Pancreatology, June 2015, Elsevier

    Dr Jerome Cros

  102. Neoadjuvant gemcitabine-oxaliplatin (GemOx) combination followed by chemoradiotherapy (CRT) in borderline pancreatic adenocarcinoma (BPC): A promising management

    Article • Pancreatology, June 2015, Elsevier

    Dr Jerome Cros

  103. Metachronous Hormonal Syndromes in Patients With Pancreatic Neuroendocrine Tumors

    Article • Annals of Internal Medicine, May 2015, American College of Physicians

    Dr Jerome Cros

  104. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis

    Article • Histopathology, May 2015, Wiley

    Dr Jerome Cros

  105. Tu1942 hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready yet? A Comparative Analysis of the Murine and the Rabbit Antibodies

    Article • Gastroenterology, April 2015, Elsevier

    Dr Jerome Cros

  106. Tu1918 Correlation Between the 18F-FDG Uptake Assessed by PET/CT and Pathological Data in Well-Differentiated Digestive Neuroendocrine Tumors

    Article • Gastroenterology, April 2015, Elsevier

    Dr Jerome Cros

  107. 665 Contrast Harmonic Endoscopic Ultrasonography Is Able to Predict Aggressivity in Pancreatic Neuroendocrine Tumors

    Article • Gastroenterology, April 2015, Elsevier

    Dr Jerome Cros

  108. Targeting the TGFβ pathway for cancer therapy

    Article • Pharmacology & Therapeutics, March 2015, Elsevier

    Dr Jerome Cros

  109. Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma

    Article • Clinical Cancer Research, December 2014, American Association for Cancer Research (AACR)

    Dr Jerome Cros

  110. Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies

    Article • Histopathology, December 2014, Wiley

    Dr Jerome Cros

  111. Experimental evidence for IS1294b-mediated transposition of the blaCMY-2 cephalosporinase gene in Enterobacteriaceae

    Article • Journal of Antimicrobial Chemotherapy, November 2014, Oxford University Press (OUP)

    Dr Jerome Cros

  112. Lessons From McCune-Albright Syndrome–Associated Intraductal Papillary Mucinous Neoplasms

    Article • JAMA Surgery, August 2014, American Medical Association (AMA)

    Dr Jerome Cros

  113. CT and MR imaging of multilocular acinar cell cystadenoma: comparison with branch duct intraductal papillary mucinous neoplasia (IPMNs)

    Article • European Radiology, June 2014, Springer Science + Business Media

    Dr Jerome Cros

  114. Long-term outcome of pancreatic neuroendocrine tumours (PNET) in von Hippel-Lindau (VHL) compared to sporadic PNET : implications for management

    Article • Pancreatology, June 2014, Elsevier

    Dr Jerome Cros

  115. Evaluation of tumor response to targeted therapies in precision-cut slices of human pancreatic neuroendocrine tumors

    Article • Pancreatology, June 2014, Elsevier

    Dr Jerome Cros

  116. O6-methylguanine DNA methyltransferase (MGMT) expression and Ki67 index predict response to temozolomide in patients with well differentiated pancreatic neuroendocrine tumors (WDPNET)

    Article • Pancreatology, June 2014, Elsevier

    Dr Jerome Cros

  117. c-MET as a prognostic biomarker and therapeutic target in patients with poor prognostic pancreatic adenocarcinoma following surgical resection

    Article • Pancreatology, June 2014, Elsevier

    Dr Jerome Cros

  118. 327 O6-Methylguanine DNA Methyltransferase (MGMT) Expression and Ki67 Index Predict Response to Temozolomide in Patients With Well Differentiated Pancreatic Neuroendocrine Tumors (WDPNET)

    Article • Gastroenterology, May 2014, Elsevier

    Dr Jerome Cros

  119. Reappraisal of Central Pancreatectomy

    Article • JAMA Surgery, April 2014, American Medical Association (AMA)

    Dr Jerome Cros

  120. MEK in cancer and cancer therapy

    Article • Pharmacology & Therapeutics, February 2014, Elsevier

    Dr Jerome Cros

  121. Hepatobiliary and Pancreatic Neoplasms in Patients With McCune-Albright Syndrome

    Article • The Journal of Clinical Endocrinology & Metabolism, January 2014, Endocrine Society

    Dr Jerome Cros

  122. Survival time estimation using Injury Severity Score (ISS) in homicide cases

    Article • Forensic Science International, December 2013, Elsevier

    Dr Philippe Charlier, Dr Jerome Cros

  123. Assessment of chronic rejection in liver graft recipients receiving immunosuppression with low-dose calcineurin inhibitors

    Article • Journal of Hepatology, December 2013, Elsevier

    Dr Jerome Cros

  124. Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours

    Article • Annals of Oncology, August 2013, Oxford University Press (OUP)

    Dr Jerome Cros

  125. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma

    Article • European Journal of Cancer, August 2013, Elsevier

    Dr Jerome Cros

  126. Stromal expression of SPARC in pancreatic adenocarcinoma

    Article • Cancer and Metastasis Reviews, May 2013, Springer Science + Business Media

    Dr Jerome Cros

  127. Tu1239 Postoperative Recurrence in Patients Operated on for Benign Intraductal Papillary Mucinous Neoplasms (IPMN)

    Article • Gastroenterology, May 2013, Elsevier

    Dr Jerome Cros

  128. Mo1404 Solid Pancreatic Tumors in Young Patients (< 40 Years Old): What Is Your Diagnosis ?

    Article • Gastroenterology, May 2013, Elsevier

    Dr Jerome Cros

  129. Postoperative recurrence in patients operated on for benign intraductal papillary mucinous neoplasms (IPMN)

    Article • Pancreatology, May 2013, Elsevier

    Dr Jerome Cros

  130. Master 2 (recherche). Tout ce que vous avez toujours voulu savoir sans jamais oser le demander !

    Article • Annales de Pathologie, April 2013, Elsevier

    Dr Jerome Cros

  131. Les carcinomes des glandes salivaires : description histologique des principaux sous-types histologiques

    Article • Revue Francophone des Laboratoires, January 2013, Elsevier

    Dr Jerome Cros

  132. Homicidal Deaths in the Western Suburbs of Paris

    Article • American Journal of Forensic Medicine & Pathology, December 2012, Wolters Kluwer Health

    Dr Philippe Charlier, Dr Jerome Cros

  133. Methylguanine DNA methyl transferase (MGMT) expression predicts response to temozolomide (TMZ) in patients with digestive neuroendocrine tumors (NETs)

    Article • Pancreatology, November 2012, Elsevier

    Dr Jerome Cros

  134. Radiographic Examination Using an X-ray Tunnel (Passagix) Before a Forensic Autopsy

    Article • American Journal of Forensic Medicine & Pathology, March 2012, Wolters Kluwer Health

    Dr Philippe Charlier, Dr Jerome Cros

  135. Rôle de l’angiogenèse et rationnel d’utilisation des thérapies ciblées dans les tumeurs endocrines digestives

    Article • Cancéro digest, January 2012, INIST-CNRS

    Dr Jerome Cros

  136. Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors

    Article • Immunity, September 2010, Elsevier

    Dr Jerome Cros, Nicolas Cagnard

  137. Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas

    Article • Oncotarget, May 2010, Impact Journals, LLC

    Dr Jerome Cros

  138. Carcinome épidermoïde des voies aérodigestives supérieures : quoi de neuf en 2009

    Article • Annales de Pathologie, September 2009, Elsevier

    Dr Jerome Cros

  139. Use of Reverse Genetics to Enhance the Oncolytic Properties of Newcastle Disease Virus

    Article • Cancer Research, September 2007, American Association for Cancer Research (AACR)

    Professor Luis Martinez-Sobrido, Dr Jerome Cros

  140. Protection against Respiratory Syncytial Virus by a Recombinant Newcastle Disease Virus Vector

    Article • Journal of Virology, February 2006, ASM Journals

    Professor Luis Martinez-Sobrido, Dr Jerome Cros

  141. Inhibition of Beta Interferon Induction by Severe Acute Respiratory Syndrome Coronavirus Suggests a Two-Step Model for Activation of Interferon Regulatory Factor 3

    Article • Journal of Virology, February 2005, ASM Journals

    Professor Luis Martinez-Sobrido, Friedemann Weber, Dr Jerome Cros

  142. An Unconventional NLS is Critical for the Nuclear Import of the Influenza A Virus Nucleoprotein and Ribonucleoprotein

    Article • Traffic, January 2005, Wiley

    Dr Jerome Cros

  143. Mapping of the RNA promoter of Newcastle disease virus

    Article • Virology, January 2005, Elsevier

    Dr Jerome Cros

  144. Induction of Cellular Immune Responses to Simian Immunodeficiency Virus Gag by Two Recombinant Negative-Strand RNA Virus Vectors

    Article • Journal of Virology, September 2004, ASM Journals

    Dr Jerome Cros

  145. Newcastle Disease Virus V Protein Is a Determinant of Host Range Restriction

    Article • Journal of Virology, September 2003, ASM Journals

    Dr Jerome Cros

  146. Trafficking of viral genomic RNA into and out of the nucleus: influenza, Thogoto and Borna disease viruses

    Article • Virus Research, September 2003, Elsevier

    Dr Jerome Cros

  147. Newcastle Disease Virus (NDV)-Based Assay Demonstrates Interferon-Antagonist Activity for the NDV V Protein and the Nipah Virus V, W, and C Proteins

    Article • Journal of Virology, January 2003, ASM Journals

    Dr Jerome Cros

  148. Recombinant Newcastle Disease Virus as a Vaccine Vector

    Article • Journal of Virology, December 2001, ASM Journals

    Dr Jerome Cros